Q3 2026 Azenta, Inc Earnings Call Transcript
Key Points
- Organic revenue grew 9% year-over-year, exceeding expectations, driven by strong performance in biorepositories and C&I.
- Multi-omics delivered year-over-year growth, with strong performance in China and Europe and modest improvement in North America.
- Completed the divestiture of B Medical Systems, simplifying the portfolio and sharpening focus on core life sciences businesses.
- Repurchased approximately 2.3 million shares for $50 million, reflecting confidence in long-term value.
- Completed remediation work on three remaining automated store systems, with most related spending now behind.
- Gross margin in multi-omics improved approximately 550 basis points year-over-year, driven by higher volumes and improved operating leverage.
- Adjusted EBITDA margin declined 60 basis points year-over-year, impacted by investments, lower volumes, and quality remediation costs.
- Automated stores and cryogenic systems continue to face softness due to macro-driven budget constraints and uneven capital deployment.
- Sanger sequencing continues to face structural market and technology transitions, pressuring margins and volumes.
- Q4 organic revenue expected to decline low single-digits due to tough comparison against record Q4 2025 performance.
- Free cash flow was negative $5 million in the quarter, impacted by working capital usage and lower deferred revenue.
- Gross margin in sample management solutions declined 750 basis points year-over-year, driven by lower volumes and quality remediation costs.
Greetings and welcome to Azenta Q3 2026 Fiscal Financial Results.
During the presentation, all participants will be in a listen-only mode. Afterwards, we will conduct a question-and-answer session.
As a reminder, this conference is being recorded Wednesday, August 5, 2026.
I will now turn the conference over to Yvonne Peron, Vice President, FB&A and Investor Relations.
Thank you, operator, and good morning, and welcome to everyone joining us today. We would like to welcome you to our earnings conference call for the third quarter of fiscal year 2026.
Our third quarter earnings press release was issued yesterday after the market and is available on our Investor Relations website located at investors.azenta.com, in addition to the PowerPoint slides and the supplementary information that will be used during the prepared remarks today.
Please note that effective the first fiscal quarter of 2025, the results of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
